trending Market Intelligence /marketintelligence/en/news-insights/trending/1ExHPL_7jAsDehiwpwqStg2 content esgSubNav
In This List

Novo Nordisk books slight dip in Q2 income, revises 2017 outlook

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Novo Nordisk books slight dip in Q2 income, revises 2017 outlook

Novo Nordisk A/S saw a slight dip in its second-quarter net profit and revised its full-year financial outlook.

The Denmark-based company reported second-quarter net income of 9.95 billion Danish kroner, or 4.01 kroner a share, compared to 9.97 billion kroner, or 3.92 a share, a year earlier.

The S&P Capital IQ consensus normalized EPS estimate for the second quarter is 3.87 kroner.

Novo Nordisk revised its financial outlook for 2017, expecting operating profit growth to be around 4 percentage points lower, compared to its previous expectation of around 1 percentage point higher. Measured in local currencies, full-year operating profit growth is now expected to be between 1% and 5% compared to the previous range of negative 1% to positive 3%.

The company also changed its full-year sales growth outlook to around 3 percentage points lower compared to the previous expectation of around 1 percentage point higher. In local currencies, 2017 sales growth is expected to be between 1% and 3%, compared to the previous range of 0% to 3%.

Second quarter gross profit was up 3% year over year to 24.23 billion kroner from 23.41 billion kroner. Non-IFRS operating profit in local currencies also rose to 13.28 billion kroner from 13.10 billion kroner in 2016.

Net sales for the quarter reached 28.64 billion kroner, up 4% year over year from 27.46 billion kroner. The company's diabetes and obesity care segment booked a 9% year-over-year growth in sales to 23.77 billion kroner.

New-generation insulin sales for the quarter, which include Tresiba, Xultophy and Ryzodeg, were up 154% year over year to 2.49 billion kroner. Diabetes treatment Victoza also booked second-quarter sales of 5.78 billion kroner, up 17% from last year.

Second quarter biopharmaceuticals sales fell to 4.87 billion kroner, down 14% from a year earlier.

Novo Nordisk's research and development costs for the quarter amounted to 3.41 billion kroner, up 2% from last year.

For the first half, the company reported net profit of 20.11 billion kroner, up 4% year over year, with first-half net sales of 57.09 billion kronor, also up 4% year over year.

As of Aug. 8, US$1 was equivalent to 6.34 Danish kroner.